June 9, 2026

The Silent Adherence Killer: Why Health Literacy Is the Pharma Problem Nobody Is Measuring

There is a patient sitting in a consulting room right now who has just received a diagnosis, a prescription, and an appointment card for three months' time. She has nodded at all the right moments. She has taken the leaflet. She has said yes when asked if she has any questions. And she has understood almost none of what was just explained to her.

She is not unusual. She is not uneducated. She is one of nearly half the adult population in Europe who, according to the WHO European Health Literacy Survey, has insufficient or problematic health literacy, meaning she lacks the ability to find, understand, appraise, and use health information in ways that support the decisions her treatment requires of her. And within weeks, the probability is high that she will be taking her medication incorrectly, if she is taking it at all.

Pharma has spent enormous energy and resource on the adherence problem over the past decade. It has measured Medication Possession Ratios and proportion of days covered, modelled first-refill rates, and designed patient support programs around reminder systems and nurse hotlines. What it has largely not done is look at the foundational reason why so many of those interventions deliver less than they promise. Health literacy is the invisible variable sitting underneath virtually every adherence failure, and until it is treated as a commercial and strategic priority rather than a public health footnote, the adherence problem will remain stubbornly, expensively unsolved.

What Health Literacy Actually Is and Why the Statistics Are Alarming

Health literacy is the ability to access, understand, appraise, and use health information and services to make decisions that promote and maintain good health. It is not simply about reading level. A highly educated professional can have excellent general literacy and poor health literacy if the clinical concepts involved in managing their condition are not explained in ways they can meaningfully absorb and act on.

The scale of the problem in Europe is striking. According to the European Health Literacy Survey, 47.6 percent of the adult population across eight EU member states, including Germany, Austria, Spain, Ireland, the Netherlands, Poland, Bulgaria, and Greece, had insufficient or problematic health literacy. At the extreme end of the spectrum, data from the WHO European Region suggests that limited health literacy affects between 25 percent of the adult population in countries with stronger health education systems and up to 72 percent in Germany, where the complexity of the healthcare system compounds the literacy challenge significantly.

The WHO is unambiguous about what limited health literacy does to health outcomes. It is associated with less participation in health promotion and disease detection activities, riskier health choices, diminished management of chronic diseases, poor adherence to medication, increased hospitalisation and rehospitalisation, increased morbidity, and premature death. These are not soft associations. They represent a direct causal chain between the ability to understand health information and the ability to act on it correctly and consistently over time.

The economic burden is equally significant. Limited health literacy causes additional costs estimated at 3 to 5 percent of total annual healthcare expenditure across the WHO European Region. In the United States, the figure has been estimated at between $106 billion and $238 billion annually in avoidable healthcare costs. And a 2025 systematic review published in Cureus found that patients with low health literacy showed 35 percent more hospital readmissions within 30 days compared to patients with adequate health literacy, a finding with direct implications for anyone thinking about the real-world cost of this problem to healthcare systems and to the patients living inside them.

The Direct Link Between Health Literacy and Non-Adherence

Despite the weight of evidence connecting health literacy to health outcomes, only 12 percent of the 387 adherence studies published since 2019 examined health literacy as a primary variable, according to the same 2025 systematic review in Cureus. The adherence research field has, for the most part, been measuring what patients do without adequately investigating why they do it, and that gap in understanding is precisely why so many adherence interventions fall short of their potential.

The evidence connecting health literacy directly to medication adherence is substantial and growing. The 2025 Cureus systematic review found that patients with low health literacy had a 2.6 times higher rate of unintentional non-adherence and 68 percent more misinterpretations of prescriptions compared to patients with adequate health literacy. A study published in Scientific Reports in 2025 examining hypertension patients found a moderate positive correlation between health literacy and medication adherence, confirming that as health literacy increases, adherence improves significantly. A 2026 meta-analysis of 42 randomised controlled trials involving 9,332 participants, published in the Journal of Evaluation in Clinical Practice, found that health literacy interventions significantly improved medication adherence with a standardised mean difference of 0.69, a clinically meaningful effect size.

The mechanism is not complicated once it is understood. A patient who does not fully understand why they are taking a medication is less motivated to take it consistently. A patient who cannot interpret whether a side effect they are experiencing is expected, concerning, or dangerous is more likely to stop treatment without telling their doctor. A patient who does not understand that their chronic condition requires ongoing treatment even when they feel well is likely to discontinue when symptoms improve. These are not motivational failures. They are knowledge failures, and they are preventable.

Why This Is a Commercial Problem, Not Just a Clinical One

The commercial implications of health literacy have been almost entirely absent from the pharma brand and commercial conversation, and that absence is costing companies money in ways that are currently attributed to other causes.

When a patient discontinues a specialty biologic after six weeks because they are confused about whether their fatigue is a side effect or a sign the therapy is not working, that discontinuation appears in brand data as a persistence failure. When a patient with a chronic condition fills their first prescription but does not refill, that appears as primary non-adherence. When a patient reduces their dose because they are worried about side effects they cannot contextualise, that appears as sub-therapeutic usage. In all three cases, the underlying driver is a health literacy failure, but the commercial reporting system has no mechanism to identify it as such, and so the intervention designed to address it is unlikely to target the right problem.

This matters for the ROI calculation around patient support investment. A patient support program that sends weekly reminder messages to a patient who stopped taking their medication because they did not understand how it worked will generate zero adherence improvement regardless of how many messages it sends. A program that identifies the knowledge gap, addresses it with accessible, contextually relevant education at the right moment in the treatment journey, and confirms comprehension before moving on, has a fundamentally different probability of changing behaviour.

A review of 29 studies synthesising the relationship between health literacy and healthcare costs, published in Health Services Management Research, found that limited health literacy was an important predictor of inappropriate healthcare utilisation, with people who had problematic health literacy showing lower self-efficacy and higher rates of avoidable contact with the healthcare system. For pharma commercial teams, the translation is direct: patients who understand their therapy stay on it longer, generate more prescription volume, produce better real-world effectiveness data, and are less likely to switch to a competitor after a confusion-driven discontinuation.

What Makes Health Literacy Particularly Acute in Specialty and Chronic Disease Therapy

The health literacy challenge is not evenly distributed across therapeutic areas. It is most acute precisely where the commercial stakes are highest.

Specialty biologics for immunology and oncology, oral therapies for metabolic conditions, and maintenance therapies for cardiovascular and respiratory diseases all share characteristics that amplify the health literacy challenge. They involve complex mechanisms of action that patients need to understand to maintain motivation. They produce side effect profiles that require contextual interpretation to manage without discontinuing. They require consistent daily or weekly behaviour over extended periods during which patients may feel well and question whether ongoing treatment is necessary. And they are often prescribed to older patients, patients with multiple comorbidities, and patients in lower socioeconomic groups, all of whom disproportionately experience limited health literacy according to the WHO European data.

A 2025 systematic review in BMC Public Health examining health literacy and medication adherence specifically in patients from ethnic minority backgrounds with Type 2 diabetes found that the relationship between limited health literacy and non-adherence was compounded in these populations, with structural barriers including language, cultural framing of illness, and trust in the healthcare system all interacting with the foundational literacy challenge. The implication is not that health literacy is irrelevant for mainstream patient populations but that it is most consequential in the patient groups where adherence is already hardest to achieve.

Why Traditional Patient Education Has Failed and What the Evidence Says About What Works

The pharmaceutical industry's default response to the patient education challenge has been the patient information leaflet. It is produced by medical writers, reviewed by regulatory affairs teams, validated for linguistic accuracy, and thoroughly unread by the vast majority of the patients it is designed to inform. Research consistently shows that health literacy-appropriate written materials require reading levels equivalent to those of a ten to twelve year old to be accessible to most adult patient populations, and the average pharmaceutical product leaflet is written at a substantially higher level than this.

The research on what actually improves health literacy and consequently adherence points clearly toward a different model. A systematic review of digital health interventions and health literacy published in medRxiv in 2025, covering 39 studies from 2013 to 2024, found that digital health interventions including multimedia tools and remote educational sessions consistently improved health literacy across diverse patient populations when they were designed with accessibility, interactivity, and personalisation in mind. A systematic review in PMC examining digital health literacy interventions found that they typically resulted in enhanced health literacy, improved medication adherence, and higher self-confidence, particularly benefiting the marginalised communities that bear the highest burden of limited health literacy.

The critical design requirements that emerge consistently from the evidence are not complex but they are systematically violated by most pharma patient education programs. Content needs to be delivered in plain, accessible language that assumes no medical knowledge. It needs to be contextually timed, arriving when it is relevant to what the patient is actually experiencing rather than front-loaded at the point of diagnosis when information overload is at its peak. It needs to be interactive rather than passive, allowing patients to ask questions and confirm their understanding rather than simply receive information. And it needs to be continuous rather than episodic, recognising that health literacy is not built through a single educational encounter but through repeated, relevant, progressively deeper engagement with information over the course of a treatment journey.

The Practical Implications for Patient Support Program Design

Translating the health literacy evidence into practical patient support program design requires three shifts in how most pharma companies currently think about patient education.

The first shift is from information provision to comprehension confirmation. Most patient support programs are designed to deliver information. The evidence suggests that the problem is not the delivery of information but the confirmation that it has been understood in a way that changes behaviour. Patient education programs need feedback mechanisms that allow patients to demonstrate comprehension and that flag when a patient's understanding of a key concept, such as why they need to continue treatment when feeling well, or how to distinguish an expected side effect from one that requires clinical attention, falls below the threshold needed to support adherent behaviour.

The second shift is from generic to personalised education pathways. The health literacy challenge is not uniform across patients, and the knowledge gaps that drive non-adherence differ between patients depending on their prior health experience, their specific concerns about the therapy, and the stage of the treatment journey they are at. A patient in the first two weeks of treatment has different educational needs from one who has been on therapy for six months and is beginning to question whether to continue. Patient support platforms that can identify which educational gap is relevant for which patient at which moment, and deliver targeted content accordingly, are operating on a fundamentally more effective model than those delivering the same content to all patients at all times.

The third shift is from a standalone education moment to a continuous learning experience. The research on health literacy interventions consistently shows that single encounters produce short-term improvements in knowledge that are not sustained over time. Lasting improvements in health literacy, of the kind that translate into sustained adherence over a twelve or twenty-four month treatment period, require ongoing educational engagement that reinforces and builds on earlier learning. This is precisely what integrated digital health platforms are designed to deliver, and it is one of the strongest arguments for embedding patient education within an engagement ecosystem that patients return to daily rather than treating it as a one-time exercise at onboarding.

The Measurement Gap That Needs to Close

For health literacy to be treated as the commercial priority it deserves, pharma commercial teams need to be able to measure it and connect it to outcomes they already care about. At present, most brand teams cannot tell you the health literacy profile of their patient population, cannot identify at which point in the treatment journey health literacy failures are driving discontinuation, and cannot measure whether their patient support program is improving comprehension or simply delivering content.

This measurement gap is addressable. Validated short-form health literacy assessment tools exist that can be embedded in digital patient engagement platforms without creating significant patient burden. Comprehension tracking, the ability to monitor whether patients are engaging with educational content and demonstrating understanding of key concepts, is a standard feature of well-designed digital health platforms. And the connection between specific educational interventions and subsequent adherence behaviour, while requiring careful study design to establish causally, is measurable over time in ways that can inform the ongoing optimisation of patient support programs.

The companies that begin measuring health literacy as a dimension of their patient support programs today are building the diagnostic infrastructure that will allow them to design more effective interventions, justify larger patient support investments with specific ROI evidence, and differentiate their products in real-world effectiveness data in ways that serve both patients and payers.

Closing the Loop

Health literacy is not a public health problem that sits outside the commercial plan. It is a measurable, addressable driver of the adherence gap that is costing pharma companies revenue and costing patients their health outcomes simultaneously.

The 47.6 percent of European adults with insufficient or problematic health literacy are not failing to take their medications because they do not care about their health. They are failing because the systems designed to support their treatment, from the prescribing consultation to the patient leaflet to the support program, were not designed with their actual comprehension needs in mind. That design failure is correctable, and the evidence for how to correct it is clear, specific, and growing.

Pharma companies that invest in health literacy-sensitive patient support, that measure comprehension not just content delivery, that time education to the moments in the treatment journey when it will have the most impact, and that build continuous educational engagement into their patient platform strategies, will generate better real-world adherence data, stronger prescriber confidence, and more credible evidence of effectiveness than those that continue to equate patient education with patient information.

The gap between what patients know and what they need to know to stay on therapy is one of the most commercially consequential gaps in healthcare. It is also one of the most solvable. The question is simply whether pharma commercial teams are ready to start measuring it.

Discover how brite supports pharmaceutical companies in delivering health-literate patient education throughout the entire treatment journey at xo-life.com/en/brite